Thursday - October 30, 2025
AstraZeneca: ENHERTU Plus Pertuzumab Granted Priority Review in the US as 1st-Line Treatment for Patients With HER2-Positive Metastatic Breast Cancer
September 25, 2025
WILMINGTON, Delaware, Sept. 25 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progress . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products